FANCI and prostate carcinoma: In conclusion, here we identify FANCI as a potential regulator of FA pathway member expression and activity in prostate cancer and suggest that targeted therapies against FANCI could be designed and tested for the prevention of FA pathway response in treatment resistance in prostate and potentially also in other cancers.